Clinical Trials Navigator
Clinical Trials Navigator
Lesson 4 — Phase I • Phase II • Phase III • Phase IV — structured, interactive planning
How to use this tool
- Phase I: Configure SAD/MAD, escalation model, DLT window, PK/PD → get MTD/RP2D plan & safety governance.
- Phase II: Randomization, blinding, dose-ranging, endpoints → get efficacy-focused trial skeleton.
- Phase III: Multicenter confirmatory design, comparators, endpoints, regulatory view.
- Phase IV: RWE/registries, long-term safety, signal detection, labeling updates.
- Scenarios: Load the worked examples to see complete outputs.
- Outputs: Copy/print/export JSON for protocol notes.
Note: Educational planning aid — align with regulations, ICH-GCP, IRB/IEC, DSMB, and institutional SOPs.
Core ideas
Safety first (Ph I)Signal & dose (Ph II)
Confirmation (Ph III)RWE & PV (Ph IV)
SAD/MAD3+3 / BOIN / CRM
Randomization & BlindingDSMB
Phase I Planner (Lesson 4.1)
Design & Safety Governance
Fill inputs and click Build Phase I Plan.
What Phase I establishes
- Safety & tolerability, DLTs, MTD and/or RP2D
- PK (ADME) & PD signals
- Framework for later-phase dosing
Phase II Planner (Lesson 4.2)
Efficacy-Focused Trial Skeleton
Set inputs and click Build Phase II Plan.
Tips
- Pre-specify dose-ranging and analysis (e.g., MMRM/ANCOVA)
- Multiplicity control if multiple doses/endpoints
- DSMB advisable for higher-risk programs
Phase III Planner (Lesson 4.3)
Confirmatory Trial & Regulatory View
Set inputs and click Build Phase III Plan.
Regulatory lens
- Pre-specified estimands & SAP; multiplicity control
- Global site quality, central randomization/blinded adjudication
- Datasets/analysis to support NDA/MAA
Phase IV Planner (Lesson 4.4)
RWE, Pharmacovigilance & Labeling
Select inputs then click Build Phase IV Plan.
Signal detection
- Disproportionality, SCCS, new-user active comparators
- Rapid AE triage & aggregate periodic review
Load Example Scenarios
Phase I — “Cardiopril” (SAD/MAD)
60 HV; SAD 5–20 mg; MAD 7 days; DLT 28d; PK rich; DSMB.
Phase II — “Glucostop”
T2D; 200 pts; 3-arm 1:1:1; HbA1c at 12w; placebo-controlled; DB.
Phase III — “Diabetex”
1,500 pts; DB; placebo; 24w; HbA1c primary; multicenter.
Phase IV — “Hypotensix”
Registry/EHR; 10k; 5y; rare AEs + BP control; labeling updates.
Outputs
Consolidated Plan
Build any section to populate this area.
Summary Tables
Phase I — Purpose
| Aspect | Description | Example |
|---|---|---|
| Primary goals | Safety, tolerability, PK/PD; find MTD/RP2D | Oncology agent MTD and AEs |
Phase I — Design
| Aspect | Description | Example |
|---|---|---|
| Participants | 20–100 HV or patients (if higher risk) | 50 HV antihypertensive |
| Study design | SAD/MAD; dose-escalation to MTD | SAD groups increasing dose |
| Endpoints | Safety/AE/SAE; PK/PD | Half-life to set dosing freq |
Phase II — Purpose & Design
| Aspect | Description | Example |
|---|---|---|
| Purpose | Efficacy signal & continued safety | Asthma attack reduction |
| Participants | 100–300 patients with condition | 200 RA patients |
| Design | Randomized, controlled; dose-ranging | DB antidepressant vs placebo |
| Endpoints | Primary efficacy; secondary safety | Δ HbA1c; hypoglycemia AEs |
Phase III — Confirmatory Design
| Aspect | Description | Example |
|---|---|---|
| Participants | Hundreds–thousands; representative | 1,000 HTN patients |
| Design | Randomized, DB, often placebo/active | DB antidepressant Phase III |
| Endpoints | Primary clinical efficacy; safety | ↓ migraine days; AE tracking |
Phase IV — RWE & PV
| Aspect | Details | Example |
|---|---|---|
| Purpose | Long-term effectiveness & rare AEs | BP med CV outcomes monitor |
| Design | Observational registries; additional RCT | EHR cohort on new statin |
| Endpoints | Primary safety; secondary effectiveness/PROs | Liver tox incidence; QoL |
| Regulatory | Post-marketing commitments; labeling updates | Boxed warning update if needed |
Phase II — Teaching & Assessment
| Method | Description |
|---|---|
| Lecture | Slides on design/methods with visuals |
| Interactive Discussion | Ethics, challenges, real cases |
| Case Study | Design, endpoints, outcomes |
| Q&A | Clarify concepts |
| Reading | Articles/chapters on Phase II |
| Assessment | Description |
|---|---|
| Quiz | Goals, randomization, endpoints, consent |
| Practical | Design a Phase II with endpoints & safety |
